LA JOLLA PHARMACEUTICAL CO
LA JOLLA PHARMACEUTICAL CO (LJPC): 8 pipeline candidates · ~16 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.3 months
D/E -2.43 · 29% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for LA JOLLA PHARMACEUTICAL COacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$48.4M
Quarterly Burn
$9.9M
Runway
16.3 mo
Revenue
$10.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
Frequently asked questions
How many drug candidates are in LA JOLLA PHARMACEUTICAL CO's pipeline?
LA JOLLA PHARMACEUTICAL CO (LJPC) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LA JOLLA PHARMACEUTICAL CO's lead drug candidate?
LA JOLLA PHARMACEUTICAL CO's most advanced tracked candidate is cea-roche test kit (Approved) for Immunology.
What is LA JOLLA PHARMACEUTICAL CO's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LA JOLLA PHARMACEUTICAL CO has approximately 16.3 months of cash runway.
Who is the CEO of LA JOLLA PHARMACEUTICAL CO?
Larry Edwards is the chief executive officer of LA JOLLA PHARMACEUTICAL CO (LJPC).
Get the full picture on LA JOLLA PHARMACEUTICAL CO
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.